Twenty-seven states and the District of Columbia have sued the bankrupt genetic testing company 23andMe in an effort to block ...

States argue that biological samples, DNA data, health-related traits and medical records are too sensitive to be sold ...

The possible sale of 23andMe’s genetic data could set a precedent for future cases where companies look to offload ...

New York and more than two dozen other U.S. states sued 23andMe to challenge the sale of its customers' private information ...

Twenty-seven states and Washington, D.C., have filed a lawsuit to block the sale of customers’ DNA and data without their ...

Twenty-eight states argue that 23andMe must secure explicit, informed consent from all 15 million affected users before ...

People did not submit their personal data to 23andMe thinking their genetic blueprint would later be sold off to the highest ...

D.C. sue to block 23andMe's data sale amid bankruptcy proceedings. Regeneron Pharmaceuticals' $256 million acquisition faces ...

The sale of 23andMe’s genetic data has prompted a lawsuit from 27 states and the District of Columbia, seeking to block the sale of genetic material the company has collected from 15 million ...

More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to auction off personal genetic information without their customers’ knowledge ...

“New Yorkers and many others around the country trusted 23andMe with their private information and they have a right to know what will be done with their information.” The states said 23andMe ...

New York and more than two dozen other US states sued 23andMe to challenge the sale of its customers’ private information after the genetic testing company filed for bankruptcy in March.